A recently concluded phase I clinical trial involving Isis Pharmaceuticals’ antisense drug ISIS 333611 against SOD1 for the treatment of ALS reported no serious adverse effects following intrathecal injection [60]. Here, SOD1 is linked to amyotrophic lateral sclerosis.